Canine Influenza Virus H3N2;Canine Influenza Virus H3N8

Verify with FDA CVM →

348 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
348
Total Reports
36
Deaths Reported
1030.0%
Death Rate

Active Ingredients

Canine Influenza Virus H3N2;Canine Influenza Virus H3N8

Administration Routes

SubcutaneousUnknownOralNasal

Species Affected

Dog 348

Most Affected Breeds

Retriever - Labrador 32
Chihuahua 23
Retriever - Golden 21
Terrier - Bull - American Pit 17
Dachshund (unspecified) 16
Shepherd Dog - Australian 15
Terrier (unspecified) 15
Crossbred Canine/dog 14
Terrier - Yorkshire 13
Shih Tzu 13

Most Reported Reactions

Vomiting 115
Lethargy (see also Central nervous system depression in Neurological) 78
Facial swelling (see also Skin) 52
Diarrhoea 50
Anaphylaxis 46
Emesis (multiple) 31
Fever 30
Pale mucous membrane 29
Anorexia 26
Hives (see also Skin) 24
Not eating 21
Death by euthanasia 19

Outcome Breakdown

Ongoing
161 (46.3%)
Recovered/Normal
118 (33.9%)
Outcome Unknown
33 (9.5%)
Euthanized
19 (5.5%)
Died
17 (4.9%)

Data Summary

Metric Value
Total adverse event reports 348
Reports involving death 36
Case-fatality rate (reported events) 1030.0%
Distinct species in reports 1
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Canine Influenza Virus H3N2;Canine Influenza Virus H3N8 Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 348 adverse event reports referencing Canine Influenza Virus H3N2;Canine Influenza Virus H3N8, including 36 reports in which the animal died — a 1030.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Canine Influenza Virus H3N2;Canine Influenza Virus H3N8. Reported administration routes include Subcutaneous, Unknown, Oral, Nasal. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Canine Influenza Virus H3N2;Canine Influenza Virus H3N8 reports are Dog (348 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (32), Chihuahua (23), Retriever - Golden (21) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Canine Influenza Virus H3N2;Canine Influenza Virus H3N8 are Vomiting (115), Lethargy (see also Central nervous system depression in Neurological) (78), Facial swelling (see also Skin) (52), Diarrhoea (50). Of the 348 reports with a coded outcome, Ongoing is the leading category at 46.3%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Canine Influenza Virus H3N2;Canine Influenza Virus H3N8.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial